| Disease | THE PURPOSE OF THIS STUDY WAS TO DETERMINE THE EFFECTS OF A GUGGULSTERONE PHOSPHATE SALT COMPOUND ON BODY COMPOSITION AND MOOD STATES IN OVERWEIGHT ADULTS. IN THE DOUBLE-MASKED, RANDOMIZED, PLACEBO-CONTROLLED STUDY, 20 SUBJECTS WITH A BODY-MASS
INDEX >25 JG.N WERE SEPERATED INTO 1 OR 3 GROUPS. THE EXPERIMENTAL GROUP RECEIVED GUGGULSTERONES 750 MG AND PHOSPHATE 1650 MG DAILY, THE PLACEBO GROUP RECEIVED MALTODEXTRIN CAPSULES, AND THE CONTROL GROUP RECEIVED NO TREATMENT FOR 6 WEEKS.
SUBJECTS WERE INSTRUCTED TO FOLLOW THE AMERICAN HEART ASSOCIATION STEP ONE DIET AND A 3-DAY-PER WEEK CIRCUIT EXERCISE PROGRAM. BODY WEIGHT DECREASED SIGNIFICANTLY IN THE EXPERIMENTAL GROUP (3.2%,P<0.05) AND FAT MASS DECREASED SIGNIFICANTLY IN
THE EXPERIMENTAL GROUP (3.2%,P<0.05) AND FAT MASS DECREASED SIGNIFICANTLY INTHE EXPERIMENTAL (20.6%) AND CONTROL (8.6%) GROUPS(P<0.01). HOWEVER, BETWEEN-GROUP DIFFERENCES IN WEIGHT LOSS WERE NOT STATISTICALLY SIGNIFICANT. PROFILE OF MOOD STATES
(POMS)-FATIGUE DECREASED SIGNIFICANTLY IN THE EXPERIMENTAL GROUP (63.7%,P<0.01), WHEREAS POMS-VIGOR INCREASED SIGNIFICANTLY IN THE EXPERIMENTAL GROUP(32.3%,P<0.01) AND DECREASED SIGNIFICANTLY IN THE PLACEBO GROUP(15.6%,-<0.01). RESULTS OF THIS
STUDY SUGGEST THAT INGESTION OF A GUGGULSTERONE PHOSPHATE SALT COMPOUND CONCURRENT WITH REGULAR EXERCISE WILL RESULT IN A SIGNIFICANT LOSS OF BODY WEIGHT AND IMPROVED MOOD STATES. |